High efficiency generalized transduction in Escherichia coli O157:H7

F1000Research
Martin G Marinus, Anthony R Poteete

Abstract

Genetic manipulation in enterohemorrhagic E. coli O157:H7 is currently restricted to recombineering, a method that utilizes the recombination system of bacteriophage lambda, to introduce gene replacements and base changes inter alia into the genome. Bacteriophage 933W is a prophage in E. coli O157:H7 strain EDL933, which encodes the genes ( stx2AB) for the production of Shiga toxin which is the basis for the potentially fatal Hemolytic Uremic Syndrome in infected humans. We replaced the stx2AB genes with a kanamycin cassette using recombineering. After induction of the prophage by ultra-violet light, we found that bacteriophage lysates were capable of transducing to wildtype, point mutations in the lactose, arabinose and maltose genes. The lysates could also transduce tetracycline resistant cassettes. Bacteriophage 933W is also efficient at transducing markers in E. coli K-12. Co-transduction experiments indicated that the maximal amount of transferred DNA was likely the size of the bacteriophage genome, 61 kB. All tested transductants, in both E. coli K-12 and O157:H7, were kanamycin-sensitive indicating that the transducing particles contained host DNA.

References

Oct 5, 1975·Journal of Molecular Biology·N KlecknerD Botstein
Mar 23, 1968·Nature·M Meselson, R Yuan
Feb 24, 2001·Nature·N T PernaF R Blattner
Mar 10, 2001·The Journal of Clinical Investigation·M S Donnenberg, T S Whittam
Nov 14, 2002·Annual Review of Genetics·Donald L CourtLynn C Thomason
Jul 15, 1962·Proceedings of the National Academy of Sciences of the United States of America·E C HEATH, A D ELBEIN
Dec 16, 2003·BMC Molecular Biology·Kenan C Murphy, Kenneth G Campellone
Mar 26, 2004·Nature Reviews. Microbiology·James B KaperHarry L Mobley
Feb 2, 2006·FEMS Microbiology Letters·Kevin J SpearsDavid L Gally
Sep 11, 2007·DNA Repair·Anetta Nowosielska, M G Marinus

❮ Previous
Next ❯

Datasets Mentioned

BETA
GM1731
GM1748
GM9251
GM9255

Related Concepts

Related Feeds

Aminoglycosides

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.

Bacteriophage: Phage Therapy

Phage therapy uses bacterial viruses (bacteriophages) to treat bacterial infections and is widely being recognized as an alternative to antibiotics. Here is the latest research.

Aminoglycosides (ASM)

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.